Current
Research in
Ophthalmology >>

Trial of the Safety, Tolerability, and Pharmacokinetics of 3mg/eye Intravitreal Injections of Pegaptanib Sodium (Anti-VEGF Pegylated Aptamer) Given Every 6 Weeks for 54 Weeks, in Patients with Exudative Age-Related Macular Degeneration

Principal Investigator

Richard Rosen, M.D.

Enrollment Status

Completed

Objective

To characterize the safety, tolerability and pharmacokinetics of pegaptanib when given as 3.0mg/eye intravitreous injections every 6 weeks for 54 weeks in patients with subfoveal choroidal neovascularization (CNV) secondary to AMD.

Study Results

MACUGEN (Pegaptanib Sodium) treatment given every 6 weeks for up to 2 years has been shown to significantly reduce the risk of moderate vision loss in patients with all types of wet AMD. Data suggests that patients who had early wet AMD and were treated with MACUGEN had improved vision outcomes than those who started treatment later.These kinds of results highlight the importance of beginning treatment before wet AMD becomes advanced and routine activities become difficult.

For more information: ClinicalTrials.gov.

Home > Current Research > Clinical Trials in Ophthalmology > Results > T rial of the Safety, Tolerability, and Pharmacokinetics of 3mg/eye Intravitreal Injections of Pegaptanib Sodium (Anti-VEGF Pegylated Aptamer) Given Every 6 Weeks for 54 Weeks, in Patients with Exudative Age-Related Macular Degeneration